Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Structure Therapeutics Inc. logoStructure Therapeutics Inc.

GPCR · Nasdaq · USD · Market cap $1.3B · 220 employees

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.

FAIL · Does not pass the screen
16.13 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price16.13 USD at the 20 Nov 2026 close
  • Fair valueUnder review: the analyst targets sit too far from the price to cross-check it; our model's value is 4.34x the price, above our 2.00x limit.
  • Our regime readMarkdown, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-20).

Current read
Markdown ?
Screened · screened 2026-11-20
  • Trend Markdown
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price16.13 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Markdown27.67-41.7% to today ✓Distribution gives way to Markdown after a 21% slide in 9 days
2026-10-02Read Distribution35.00-53.9% to today ✓Accumulation gives way to Distribution after a 29% slide in 5 weeks
2026-08-31Read Accumulation49.35-67.3% to today Markup gives way to Accumulation
2026-07-31Read Markup48.48-66.7% to today Markdown gives way to Markup after a 13% rise in 4 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markdown label.

Structure Therapeutics Inc. holds its Markdown at $16.13. The statistical read favours the sellers, held for 68 days.

As held on the ledger · 2026-11-20
PhaseMarkdown · caution
Quantitative stateThe statistical read favours the sellers, held for 68 days
Price at the screen$16.13
ValuationN/A trailing · -7.42 forward price to earnings
Values screenFAIL · score 70.0
Beta-1.20
The Workings

Five Screens: GPCR's Results

FAIL. Interest-bearing securities

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 0.41% Below 33% Pass
Interest-bearing cash 40.82% Below 33% Fail
Receivables 56.80% Below 49% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Structure Therapeutics's business is fine, but its cash and interest-bearing securities are about 41% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when GPCR's ethical verdict changes

Today GPCR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. The analyst targets sit too far from the price to cross-check it; our model's value is 4.34x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

Method.

The Street's Range
70.00Street low 100.50Street average 145.00Street high 16.13Price

Street: 14 covering, consensus Strong Buy. Average target +523%.

Chart
The Business, in Plain Words

Clinical biotech with no profits or data

Imagine handing cash to a lab team that has never turned a profit and cannot show basic financial ratios. Structure Therapeutics is exactly that, a clinical stage player developing oral molecules for chronic disease. The opportunity rating sits at none, the ethical screen returns insufficient data, and with zero profit margin plus negative fifteen percent return on equity the business offers nothing to anchor a position.

Forward earnings sit at a negative twenty five times multiple while the share price of forty eight dollars trades at half the analyst median target. That gap looks tempting only until the complete absence of moat data and financial ratios is factored in. Without those foundations any apparent margin of safety remains an accounting mirage.

Clinical trials can fail at any stage, cash burn is constant, and the ethical gaps alone rule out further work. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-7.4x
EPS, trailing-3.90
EPS, forward-2.50
Profit margin0.0%currently unprofitable
Return on equity-20.2%not currently earning a positive return on equity
FCF yield-8.96%
Debt to equity0.46minimal debt: a conservative balance sheet
Current ratio20.75comfortably covers its short-term bills
Beta-1.20barely tracks the market's swings
Short interest, float0.14%
52-week range18.38 - 94.90
Market cap$1.3B
Employees220

GPCR-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markdown $17.36 -13.2% Entry 21
2026-11-16 Markdown $20.00 -1.7% Entry 20
2026-11-09 Markdown $20.35 +0.0% Entry 19
2026-11-08 Markdown $20.35 0.0% Entry 18
2026-11-05 Markdown $20.36 +0.0% Entry 17
2026-11-04 Markdown $20.35 -7.0% Entry 16
2026-11-03 Markdown $21.87 +0.0% Entry 15
2026-11-02 Markdown $21.87 +0.0% Entry 14
2026-11-01 Markdown $21.87 +3.2% Entry 13
2026-10-31 Markdown $21.19 +0.0% Entry 12

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on GPCR

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in GPCR's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $38.32 +7.6% · $1,076 +7.6%
2 months $54.51 -24.3% · $757 -24.3%
3 months $54.58 -24.4% · $756 -24.4%
6 months $67.44 -38.9% · $612 -38.9%
1 year $21.83 +88.9% · $1,889 +88.9%
2 years $52.91 -22.1% · $779 -22.1%
3 years $34.01 +21.3% · $1,213 +21.3%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever GPCR does next, these words stay.

Structure Therapeutics Inc. · GPCR · Markdown · $16.13
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.